Literature DB >> 2825756

Treatment of CMV retinitis in an AIDS patient.

J F Acheson1, S M Shah, D J Spalton, C Bradbeer, R N Thin.   

Abstract

We present a case of cytomegalovirus (CMV) retinitis in an AIDS patient who survived for 10 months after the start of his ocular problems. The retinitis responded to dihydroxy propoxy methyl guanine (DHPG) but relapsed four to six weeks after each course of treatment with progressive retinal destruction. One relapse was therefore treated with trisodium phosphoformate hexahydrate (Foscarnet). There are few reports of the use of this drug in the treatment of CMV retinitis with AIDS, but it appeared to be less effective in our patient than DHPG, possibly because of poor penetration of the blood-ocular barrier. A final course of outpatient maintenance therapy with DHPG failed to prevent a preterminal relapse of the retinitis. Fundus photographs demonstrated the resolution and relapse of the retinitis associated with each course of treatment. Maintenance therapy with DHPG would appear to be necessary to prevent relapse, but the logistics of this are difficult, and the effective dosage of DHPG is as yet uncertain.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2825756      PMCID: PMC1041317          DOI: 10.1136/bjo.71.11.810

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  20 in total

1.  Acquired immune deficiency syndrome. Pathogenic mechanisms of ocular disease.

Authors:  J S Pepose; G N Holland; M S Nestor; A J Cochran; R Y Foos
Journal:  Ophthalmology       Date:  1985-04       Impact factor: 12.079

2.  Foscarnet for cytomegalovirus infections.

Authors:  O Ringdén; H Wilczek; B Lönnqvist; G Gahrton; B Wahren; J O Lernestedt
Journal:  Lancet       Date:  1985-06-29       Impact factor: 79.321

3.  Foscarnet for cytomegalovirus pneumonitis.

Authors:  J F Apperley; R E Marcus; J M Goldman; D G Wardle; P J Gravett; A Chanas
Journal:  Lancet       Date:  1985-05-18       Impact factor: 79.321

4.  Inhibition of human T-cell lymphotropic virus type III in vitro by phosphonoformate.

Authors:  E G Sandstrom; J C Kaplan; R E Byington; M S Hirsch
Journal:  Lancet       Date:  1985-06-29       Impact factor: 79.321

5.  A prospective study of the ophthalmologic findings in the acquired immune deficiency syndrome.

Authors:  W R Freeman; C W Lerner; J A Mines; R S Lash; A J Nadel; M B Starr; M L Tapper
Journal:  Am J Ophthalmol       Date:  1984-02       Impact factor: 5.258

6.  Concurrent herpes simplex and cytomegalovirus retinitis and encephalitis in the acquired immune deficiency syndrome (AIDS).

Authors:  J S Pepose; L H Hilborne; P A Cancilla; R Y Foos
Journal:  Ophthalmology       Date:  1984-12       Impact factor: 12.079

7.  Treatment of cytomegalovirus retinitis with 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine.

Authors:  D Felsenstein; D J D'Amico; M S Hirsch; D A Neumeyer; D M Cederberg; P de Miranda; R T Schooley
Journal:  Ann Intern Med       Date:  1985-09       Impact factor: 25.391

8.  Intravenous foscarnet for the treatment of severe cytomegalovirus infection in allograft recipients.

Authors:  G Klintmalm; B Lönnqvist; B Oberg; G Gahrton; J O Lernestedt; G Lundgren; O Ringdén; K H Robert; B Wahren; C G Groth
Journal:  Scand J Infect Dis       Date:  1985

9.  Activity of 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine in the treatment of cytomegalovirus pneumonia.

Authors:  D H Shepp; P S Dandliker; P de Miranda; T C Burnette; D M Cederberg; L E Kirk; J D Meyers
Journal:  Ann Intern Med       Date:  1985-09       Impact factor: 25.391

Review 10.  Antiviral effects of phosphonoformate (PFA, foscarnet sodium).

Authors:  B Oberg
Journal:  Pharmacol Ther       Date:  1982       Impact factor: 12.310

View more
  2 in total

1.  Foscarnet as treatment for cytomegalovirus retinitis following bone marrow transplantation.

Authors:  P S Ganly; C Arthur; J M Goldman; W E Schulenburg
Journal:  Postgrad Med J       Date:  1988-05       Impact factor: 2.401

2.  Toxicity of intravitreal injection of foscarnet in the rabbit eye.

Authors:  S C She; G A Peyman; J A Schulman
Journal:  Int Ophthalmol       Date:  1988       Impact factor: 2.031

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.